Mereo BioPharma Group plc (MAH0) - Net Assets

Latest as of December 2025: €40.92 Million EUR ≈ $47.84 Million USD

Based on the latest financial reports, Mereo BioPharma Group plc (MAH0) has net assets worth €40.92 Million EUR (≈ $47.84 Million USD) as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€45.92 Million ≈ $53.68 Million USD) and total liabilities (€5.00 Million ≈ $5.85 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check Mereo BioPharma Group plc tangible equity quality to evaluate the tangible quality of the company's equity base.

Key Net Assets Metrics

Metric Value
Current Net Assets €40.92 Million
% of Total Assets 89.11%
Annual Growth Rate -7.08%
5-Year Change -53.51%
10-Year Change N/A
Growth Volatility 46.61

Mereo BioPharma Group plc - Net Assets Trend (2016–2025)

This chart illustrates how Mereo BioPharma Group plc's net assets have evolved over time, based on quarterly financial data. See MAH0 defensive interval ratio to measure how many days the company can operate on defensive assets alone.

Annual Net Assets for Mereo BioPharma Group plc (2016–2025)

The table below shows the annual net assets of Mereo BioPharma Group plc from 2016 to 2025. For live valuation and market cap data, see Mereo BioPharma Group plc market cap and net worth.

Year Net Assets Change
2025-12-31 €40.92 Million
≈ $47.84 Million		 -32.89%
2024-12-31 €60.97 Million
≈ $71.28 Million		 +20.64%
2023-12-31 €50.54 Million
≈ $59.08 Million		 -18.31%
2022-12-31 €61.87 Million
≈ $72.33 Million		 -29.70%
2021-12-31 €88.00 Million
≈ $102.88 Million		 +687.82%
2020-12-31 €-14.97 Million
≈ $-17.50 Million		 -137.19%
2019-12-31 €40.26 Million
≈ $47.06 Million		 +22.84%
2018-12-31 €32.77 Million
≈ $38.31 Million		 -47.55%
2017-12-31 €62.48 Million
≈ $73.05 Million		 -21.16%
2016-12-31 €79.26 Million
≈ $92.66 Million		 --

Equity Component Analysis

This analysis shows how different components contribute to Mereo BioPharma Group plc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

  • Retained earnings have decreased by 46043875900.0% over the analyzed period, potentially due to dividend distributions or operating losses.

Current Equity Component Breakdown (December 2025)

Component Amount Percentage
Other Components €541.93 Million 1324.50%
Total Equity €40.92 Million 100.00%

Mereo BioPharma Group plc Competitors by Market Cap

The table below lists competitors of Mereo BioPharma Group plc ranked by their market capitalization.

Company Market Cap
Clean TEQ Water Ltd
AU:CNQ
 $31.92 Million
Fridenson
TA:FRDN
 $31.94 Million
Carbon Streaming Corp
NEO:NETZ
 $31.94 Million
Logindo Samudramakmur Tbk
JK:LEAD
 $31.94 Million
Unisync Corp
TO:UNI
 $31.91 Million
Dcon Products Public Company Limited
BK:DCON
 $31.90 Million
TDb Split Corp
TO:XTD
 $31.88 Million
Beamtree Holdings Ltd
AU:BMT
 $31.88 Million

Equity Growth Attribution

This analysis shows how different factors contributed to changes in Mereo BioPharma Group plc's equity between the two most recent reporting periods.

Equity Growth Insights

  • From 2024 to 2025, total equity changed from 60,969,000 to 40,916,000, a change of -20,053,000 (-32.9%).
  • Net loss of 41,878,000 reduced equity.
  • New share issuances of 39,000 increased equity.
  • Other factors increased equity by 21,786,000.

Equity Change Factors (2024 to 2025)

Factor Impact Contribution
Net Income €-41.88 Million -102.35%
Share Issuances €39.00K +0.1%
Other Changes €21.79 Million +53.25%
Total Change €- -32.89%

Book Value vs Market Value Analysis

This analysis compares Mereo BioPharma Group plc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

  • Current price-to-book ratio: 5.13x
  • The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
  • The price-to-book ratio has increased from 0.30x to 5.13x over the analyzed period, suggesting growing market confidence.

Historical Price-to-Book Ratios

Date Book Value per Share Market Price P/B Ratio
2017-12-31 €0.88 €0.26 x
2018-12-31 €0.46 €0.26 x
2019-12-31 €0.41 €0.26 x
2020-12-31 €-0.04 €0.26 x
2021-12-31 €0.15 €0.26 x
2022-12-31 €0.10 €0.26 x
2023-12-31 €0.07 €0.26 x
2024-12-31 €0.08 €0.26 x
2025-12-31 €0.05 €0.26 x

Capital Efficiency Dashboard

This dashboard shows how efficiently Mereo BioPharma Group plc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

  • Current Return on Equity (ROE): -102.35%
  • The company may be facing challenges in efficiently utilizing shareholder equity.
  • DuPont Analysis Breakdown:
  • • Net Profit Margin: -8375.60%
  • • Asset Turnover: 0.01x
  • • Equity Multiplier: 1.12x
  • Recent ROE (-102.35%) is below the historical average (-55.46%), suggesting potential challenges in capital efficiency.

Historical Capital Efficiency Metrics

Year Return on Equity Net Profit Margin Asset Turnover Equity Multiplier Economic Value Added
2016 -35.82% 0.00% 0.00x 1.09x €-36.32 Million
2017 -62.09% 0.00% 0.00x 1.54x €-45.05 Million
2018 -97.74% 0.00% 0.00x 2.05x €-35.31 Million
2019 -86.56% 0.00% 0.00x 2.15x €-38.87 Million
2020 0.00% 0.00% 0.00x 0.00x €-162.13 Million
2021 14.46% 34.90% 0.29x 1.44x €3.92 Million
2022 -55.27% 0.00% 0.00x 1.42x €-40.38 Million
2023 -58.31% -294.66% 0.15x 1.32x €-34.52 Million
2024 -70.94% 0.00% 0.00x 1.25x €-49.35 Million
2025 -102.35% -8375.60% 0.01x 1.12x €-45.97 Million

Industry Comparison

This section compares Mereo BioPharma Group plc's net assets metrics with peer companies in the Biotechnology industry.

Industry Context

  • Industry: Biotechnology
  • Average net assets among peers: $1,435,678,106
  • Average return on equity (ROE) among peers: -30.54%

Peer Company Comparison

Company Net Assets Return on Equity Debt-to-Equity Market Cap
Mereo BioPharma Group plc (MAH0) €40.92 Million -35.82% 0.12x $31.92 Million
PROQR THERAPEUTICS EO-04 (0PQ) $66.68 Million -96.62% 1.57x $142.34 Million
TIZIANA LIFE SCIENCES LTD (0RP) $5.54 Million -319.56% 1.20x $141.34 Million
Theravance Biopharma Inc (0TB) $441.80 Million 197.40% 0.37x $828.57 Million
I-MAB SPONS.ADS/1 -0001 (0VY) $230.94 Million -20.03% 0.13x $179.82 Million
PreveCeutical Medical Inc (18H) $-4.64 Million 0.00% 0.00x $3.34 Million
Argen-X (1AE) $1.05 Billion -15.51% 0.36x $41.67 Billion
WAVE LIFE SCIENCES LTD. (1U5) $-45.09 Million 0.00% 0.00x $1.10 Billion
BIOCURE TECHNOLOGY INC. (1WH) $1.60 Million -113.13% 0.23x $960.84K
ZAI LAB LTD0000006 (1ZLB) $715.50 Million -24.53% 0.64x $1.82 Billion
BioNTech SE (22UA) $11.89 Billion 86.54% 0.33x $20.05 Billion

About Mereo BioPharma Group plc

F:MAH0 Germany Biotechnology
Market Cap
$49.26 Million
€42.14 Million EUR
Market Cap Rank
#23596 Global
#2056 in Germany
Share Price
€0.26
Change (1 day)
+8.20%
52-Week Range
€0.20 - €2.45
All Time High
€4.48
Categories
Companies in Germany Biotechnology
About

Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of rare diseases in the United Kingdom and the United States. The company develops Setrusumab, an antibody for the treatment of osteogenesis imperfecta; Alvelestat, an oral small molecule that is in Phase II clinical trial to treat Alpha-1 anti-trypsin deficiency associated lung dise… Read more